This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).
这项发明属于药物
化学领域。特别是,该发明涉及一类新的小分子,具有
喹啉或
噻吨酮(或类似)结构,可作为自噬
抑制剂和/或组蛋白脱乙酰酶
抑制剂发挥作用,并用作治疗以异常自噬活性 和/或异常H
DAC活性(例如,癌症、肺动脉高压、糖尿病、神经退行性疾病、衰老、心脏病、类风湿性关节炎、感染性疾病、病毒感染(例如,COVID-19)引起的状况和症状)为特征的疾病的治疗方法。